Barro, C., Affonso, A. A. M., Waquar, A., Aragao, N., Bakheet, A., Cajiao, K., Souza, A. B. C., Díaz, L. A. Q., Fowler, C. M., Herrera, R., Huapaya, L. A. N., Kornienko, K., Magalhães, A. M. V., Menezes, T. d. O., Mordojovich, M.-A., Nosé, R., Pan, H., Persivale, K. S., Poveda, C., Ramos, C., Rodrigues, M. A., Ruiz, J. M. V., Soares, R., & DangHan, X. (2018). The INCA trial: a multicenter, randomized, phase II, open-label clinical trial to evaluate the combination therapy with Ipilimumab plus Nivolumab versus Chemotherapy (Pemetrexate-Cisplatin) in patients with Advanced non-squamous NSCLC naive to treatment. Principles and Practice of Clinical Research, 4(1), 6-13. Retrieved from https://journal.ppcr.org/index.php/ppcrjournal/article/view/62